Free Preview
Moderna has been a stock market darling but its share price has fallen by around half from its 52-week high. Now, problems are piling up for the company which has slashed its revenue projections largely based on lower-than-expected sales of its COVID-19 vaccine. The company also faces a lawsuit from the U.S. National Institutes of Health over ownership of that vaccine. Those problems, along with concerns about the future when the pandemic ends,have been a drag on the company’s stock which could fall further. Maxx Chatsko joins “7investing Now” to break down what’s happening and share what might happen next.
